Overview
Reverie Labs uses computational drug discovery to speed up cancer therapy development. It builds workflows that blend machine learning, cheminformatics, physics, biology, and chemistry to identify and optimize drug candidates, predicting properties and guiding chemistry decisions. The company earns revenue through strategic partnerships with pharmaceutical firms (such as Roche/Genentech) and investor funding. Its goal is to move promising compounds from discovery to clinical trials faster by delivering practical, collaborative computational tools for medicinal chemistry challenges.
Work here?Claim your company
Simplify's take
What believers are saying
- Ginkgo said on May 19, 2025 it is using Reverie’s platform for customer programs.
- Pharmaphorum reported on Nov. 9, 2026 that Ginkgo bought Reverie’s model-training infrastructure.
- Reverie’s acquisition price included $3.5 million in Ginkgo stock for four employees, validating value.
What critics are saying
- Ginkgo Bioworks bought Reverie’s assets in 2024, ending standalone company status.
- Four Reverie employees joined Ginkgo, signaling a small surviving team and limited employer scale.
- If Ginkgo deprioritizes Reverie’s platform, the brand disappears into a larger integration program.
What makes Reverie Labs unique
- Reverie Labs built ML drug-discovery infrastructure strong enough for Ginkgo’s 2024 acquisition.
- Its platform targeted kinase inhibitors, a hard oncology niche with high-value pharma demand.
- The team’s foundation-model training software became a transferable asset, not just a services stack.
Help us improve and share your feedback! Did you find this helpful?
Funding
Notable Investors:
Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Industry standards
Ind Avg. $15M
$3.7M
$5M
$8.2M
$15M
$25M
$30M